TVTX News and Press, Travere Therapeutics Inc Com From 02/23/24

CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy Canada NewsWire Committee for Medicinal Products for Human Use (CHMP) recommends approval of the conditional marketing authorization (CMA) for sparsentan ...

2024-02-16 05:05:19 ET Travere Therapeutics, Inc. (TVTX) Q4 2023 Earnings Conference Call February 15, 2024 16:30 ET Company Participants Anne Crotteau - Investor Relations Eric Dube - Chief Executive Officer Jula Inrig - Chief Medical Officer Peter Heerma - ...

2024-02-15 16:05:21 ET More on Travere Therapeutics Travere Therapeutics: Restructuring Away From Disaster Travere Therapeutics Q4 2023 Earnings Preview Travere inks licensing deal for sparsentan in Asia Seeking Alpha’s Quant Rating on Travere Therapeu...

Received 459 new patient start forms (PSFs) for FILSPARI ® (sparsentan) in Q4 2023; Total of 1,452 PSFs received in 2023 Company nearing submission of sNDA to convert U.S. accelerated approval of FILSPARI in IgAN to full approval CHMP opinion on potential approv...

SAN DIEGO, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced it will report fourth quarter and full year 2023 financial results on Thursday, February 15, 2024, after the close of the U.S. financial markets. The Company will host a conference call and webc...

SAN DIEGO, Feb. 01, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that company management will present at the Guggenheim 6th Annual Biotechnology Conference on Thursday, February 8, 2024, at 11:30 a.m. ET. A live webcast will be accessible on the Investo...

2024-01-29 22:33:19 ET Summary Travere Therapeutics faces challenges following disappointing data from its PROTECT trial in September 2023. The FDA granted accelerated approval for Travere's FILSPARI, but its continued approval is contingent upon confirmation of clinical benefit i...

2024-01-25 17:55:11 ET More on Travere Therapeutics Travere Therapeutics expects Q4 net product sales from continuing operations to be about $40M Travere to seek FDA approval for Filspari in IgAN but not FSGS Travere Therapeutics, Inc. (TVTX) Q3 2023 Earnings Call Tr...

SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (NASDAQ: TVTX) announced that it has entered into an exclusive licensing agreement with Renalys Pharma, Inc., to bring sparsentan, a dual endothelin angiotensin receptor antagonist for the treatment of IgA nephropathy, to pa...

2024-01-25 15:30:27 ET Summary Vera Therapeutics, Inc. stock price soared over 35% today as it announced positive results from the open label extension of its Phase 2b ORIGIN clinical trial for atacicept in IgA nephropathy. The company's stock is up over 160% in the past year and ...